|
Alzheimer Disease
Citations 371-380 of 489 total displayed.
|
Past content
(since Jan 1998):
|
- Original Contributions
Attention and Fluctuating Attention in Patients With Dementia With Lewy Bodies and Alzheimer Disease
- Clive Ballard; John O'Brien; Alistair Gray; Franchesca Cormack; Gareth Ayre; Elise Rowan; Peter Thompson; Romola Bucks; Ian McKeith; Matthew Walker; Martin Tovee
Arch Neurol 2001; 58: 977-982.
[Abstract]
[Full text]
[PDF]
- Editorials
Cerebrospinal Fluid ß-Amyloid and Tau Proteins for the Diagnosis of Alzheimer Disease
- David Knopman
Arch Neurol 2001; 58: 349-350.
[Extract]
[Full text]
[PDF]
- Editorials
New Biochemical Markers in Alzheimer Disease
- Ramon Diaz-Arrastia; Fred Baskin
Arch Neurol 2001; 58: 354-356.
[Extract]
[Full text]
[PDF]
- Basic Science Seminars in Neurology
Glutamate Transporters in Neurologic Disease
- Nicholas J. Maragakis; Jeffrey D. Rothstein
Arch Neurol 2001; 58: 365-370.
[Extract]
[Full text]
[PDF]
- Original Contributions
Evaluation of CSF-tau and CSF-Aß42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
- Niels Andreasen; Lennart Minthon; Pia Davidsson; Eugeen Vanmechelen; Hugo Vanderstichele; Bengt Winblad; Kaj Blennow
Arch Neurol 2001; 58: 373-379.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Ratio of 8-Hydroxyguanine in Intact DNA to Free 8-Hydroxyguanine Is Increased in Alzheimer Disease Ventricular Cerebrospinal Fluid
- Mark A. Lovell; William R. Markesbery
Arch Neurol 2001; 58: 392-396.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease
- John C. Morris; Martha Storandt; J. Phillip Miller; Daniel W. McKeel; Joseph L. Price; Eugene H. Rubin; Leonard Berg
Arch Neurol 2001; 58: 397-405.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Mild Cognitive Impairments Predict Dementia in Nondemented Elderly Patients With Memory Loss
- Andrea Bozoki; Bruno Giordani; Judith L. Heidebrink; Stanley Berent; Norman L. Foster
Arch Neurol 2001; 58: 411-416.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression
- Martin R. Farlow; Ann Hake; John Messina; Richard Hartman; Jeffrey Veach; Ravi Anand
Arch Neurol 2001; 58: 417-422.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Open-Label, Multicenter, Phase 3 Extension Study of the Safety and Efficacy of Donepezil in Patients With Alzheimer Disease
- Rachelle S. Doody; David S. Geldmacher; Barry Gordon; Carlos A. Perdomo; Raymond D. Pratt; for the Donepezil Study Group
Arch Neurol 2001; 58: 427-433.
[Abstract]
[Full text]
[PDF]
|
|
